Top 50 Biotech Investors in Europe 2026

Specialty pharma, biotech and medical devices across all stages, weighted to private European companies; around €294m raised across three funds since 2008.

Early-stage therapeutics and medical technology; one of two Irish-headquartered firms on the list.

Dedicated advanced therapies specialist: cell, gene, RNA and targeted therapeutics only.

Venture plus clinical co-development capital; part of Carlyle since 2022, which widens the cheque size materially.

Transatlantic early-stage therapeutics, frequently as founding investor rather than a later participant.

Australia-founded with a real UK and European platform; a route into APAC syndicates for European assets.

Seed and company creation out of UK and US research universities — origination the London funds rarely reach.

Evergreen venture arm of medical research charity LifeArc, investing off balance sheet in translational therapeutics and platforms from seed to Series B.

Asset-centric model — single-asset companies built around one drug candidate, with pharma LPs on the register.

Multi-strategy across biotech venture, a dedicated dementia fund and public equities.

LSE-listed evergreen company builder that founds and holds therapeutics businesses long-term — and marks them quarterly.